--- title: "I-Mab (NASDAQ:IMAB) Stock Price Down 3.8%" description: "I-Mab (NASDAQ:IMAB) stock price dropped 3.8% during mid-day trading on Friday. The stock has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $1.73. A hedge fund recently" type: "news" locale: "en" url: "https://longbridge.com/en/news/210640398.md" published_at: "2024-08-03T07:12:53.000Z" --- # I-Mab (NASDAQ:IMAB) Stock Price Down 3.8% > I-Mab (NASDAQ:IMAB) stock price dropped 3.8% during mid-day trading on Friday. The stock has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $1.73. A hedge fund recently bought a new stake in I-Mab stock. I-Mab is a clinical stage biopharmaceutical company that develops biologics to treat cancer and autoimmune disorders. I-Mab (NASDAQ:IMAB - Get Free Report) shares dropped 3.8% during mid-day trading on Friday . The stock traded as low as $1.23 and last traded at $1.26. Approximately 150,879 shares changed hands during trading, a decline of 56% from the average daily volume of 345,044 shares. The stock had previously closed at $1.31. ## Wall Street Analyst Weigh In Separately, Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of I-Mab in a research note on Friday, April 12th. **Read Our Latest Analysis on I-Mab** ## I-Mab Stock Down 3.8 % The stock has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $1.73. ## Hedge Funds Weigh In On I-Mab A hedge fund recently bought a new stake in I-Mab stock. abrdn plc bought a new position in I-Mab (NASDAQ:IMAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 162,580 shares of the company's stock, valued at approximately $309,000. abrdn plc owned 0.20% of I-Mab as of its most recent filing with the SEC. 38.38% of the stock is currently owned by institutional investors and hedge funds. ## About I-Mab (Get Free Report) I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. ## Featured Articles - Five stocks we like better than I-Mab - Buy P&G Now, Before It Sets A New All-Time High - Should You Invest in Bitcoin? Pros and Cons - Insider Buying Explained: What Investors Need to Know - Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts - How to Choose Top Rated Stocks - Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → Biggest opportunity for monthly dividends in the energy sector (From Investors Alley) (Ad)## Should you invest $1,000 in I-Mab right now? Before you consider I-Mab, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list. While I-Mab currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IMAB.US - I-Mab](https://longbridge.com/en/quote/IMAB.US.md) - [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | IHI, IHE, ARKG：專業醫療保健 ETF 可以助力提升投資組合表現 | 專業醫療保健 ETF 可以通過關注製藥、醫療設備和生物技術等特定領域來增強投資組合。值得注意的 ETF 包括 iShares 美國醫療設備 ETF（IHI），其中包含波士頓科學和美敦力等公司；iShares 美國製藥 ETF（IHE），包括 | [Link](https://longbridge.com/en/news/276080275.md) | | Ence 計劃在 2027 年前在 Navia 生物工廠裁減 44 個職位 | Ence Energia y Celulosa SA：在納維亞生物工廠達成集體解僱協議協議包括到 2027 年終止 44 份勞動合同潛在年節省 22 歐元/噸和 2600 萬歐元現金流出到 2028 年 6 月前最多 40 個內部調動 | [Link](https://longbridge.com/en/news/276430844.md) | | 美達生物將註銷價值 27 億韓元的自有股份 | Metabiomed Co Ltd :METABIOMED: 將取消價值 27 億韓元的自有股份 | [Link](https://longbridge.com/en/news/276408478.md) | | PureTech Health PLC 贊助的美國存託憑證（NASDAQ:PRTC）空頭頭寸最新動態 | PureTech Health PLC（納斯達克代碼：PRTC）在 1 月份的空頭頭寸減少了 18.8%，截至 1 月 30 日，共有 3,860 股被賣空。根據平均交易量 3,245 股，目前的空頭頭寸比率為 1.2 天。該股票交易價格為 | [Link](https://longbridge.com/en/news/276082967.md) | | Zweig DiMenna Associates LLC 購入了 CareDx, Inc.的 348,400 股股票，股票代碼為$CDNA | Zweig DiMenna Associates LLC 在第三季度將其在 CareDx, Inc. (NASDAQ:CDNA) 的持股增加了 153.8%，收購了 348,400 股，使其總持股達到 575,000 股，價值 836 萬美 | [Link](https://longbridge.com/en/news/276125724.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.